Phase III Randomized Trial of 12 Months VS 3 Months of Paclitaxel in Patients with Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy (Intergroup)

Value of Anti-Cancer Drugs in SWOG Phase III Clinical Trials: Evidence from Multiple Evaluation Mechanisms

V Nghiem;R Vaidya;M Banegas;D Hershman;J Unger AcademyHealth Annual Research Meeting (June 23-26, 2018, Seattle, WA), poster #B-335

Association between body mass index and cancer survival in a pooled analysis of 22 clinical trials

H Greenlee;J Unger;M Leblanc;S Ramsey;D Hershman Cancer Epidemiology Biomarkers & Prevention 2017 Jan;26(1):21-29; 2016 Dec 16. [Epub ahead of print]

PMid: PMID27986655 | PMC number: PMC5370550

Association between BMI at treatment initiation and cancer survival across multiple SWOG trials

H Greenlee;J Unger;M Leblanc;D Hershman AACR Research International Conference on Frontiers on Cancer Research Prevention (Sept 28-Oct 1, 2014, New Orleans, LA; poster

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: Follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial [PMC2836168; PMID19447479]

M Markman;PY Liu;J Moon;B Monk;L Copeland;S Wilczynski;D Alberts Gynecologic Oncology 114(2):195-198

An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy [PMID17704410]

PY Liu;DS Alberts;BJ Monk;M Brady;J Moon;M Markman Journal of Clinical Oncology 25(24):3615-3620

A modified CA-125 progression criterion in ovarian cancer (OC) patients (pts) receiving maintenance treatment following complete clinical response (cCR) to primary therapy

P Liu;J Moon;DS Alberts;BJ Monk;M Brady;M Markman Proc of the ASCO, Journal of Clinical Oncology 24(18S):#5080

Survival (S) of ovarian cancer (OC) patients (pts) treated on SWOG9701/GOG178: 12 versus (v) 3 cycles (C) of monthly single-agent paclitaxel (PAC) following attainment of a clinically-defined complete response (CR) to platinum (PLAT)/PAC

M Markman;PY Liu;S WIlczynski;B Monk;LJ Copeland;D Alberts Proc of the ASCO, Journal of Clinical Oncology 24(18S):#5005

Pretreatment CA-125 and risk of relapse in advanced ovarian cancer

M Markman;PY Liu;M Rothenberg;BJ Monk;M Brady;DS Alberts Journal of Clinical Oncology 24(9):1454-1458

Relationship between pretreatment CA-125 level and risk of relapse in advanced ovarian cancer (AOC) patients in a complete clinical response (CCR) who received "maintenance therapy"

PY Liu;DS Alberts;BJ Monk;M Brady;M Markman Proc of the ASO, JCO 23(16S):458s (#5013)

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial

M Markman;PY Liu;S Wilczynski;B Monk;LJ Copeland;RD Alvarez;C Jiang;D Alberts Journal of Clinical Oncology 21(13):2460-2465

Phase 3 randomized trial of 12 versus 3 months of single-agent paclitaxel in patients with advanced ovarian cancer who attained a clinically defined complete response to platinum/paclitaxel-based chemotherapy, a Southwest Oncology Group trial

M Markman;PY Liu;S Wilczynski;BJ Monk;L Copeland;DS Alberts Gynecologic Oncology 84:479(#1)